Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: iron oxide black; ethylcellulose; colloidal anhydrous silica; copovidone; titanium dioxide; magnesium stearate; povidone; gelatin; microcrystalline cellulose; purified talc; iron oxide red; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine medis xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - oxycodone hydrochloride, quantity: 10 mg - capsule, hard - excipient ingredients: gelatin; microcrystalline cellulose; indigo carmine; magnesium stearate; iron oxide yellow; titanium dioxide; iron oxide red; sodium laureth sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oxycodone medis is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - oxycodone hydrochloride, quantity: 10 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; iron oxide red; indigo carmine; magnesium stearate; iron oxide yellow; microcrystalline cellulose; sodium laureth sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oxycodone medis is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - oxycodone hydrochloride, quantity: 5 mg - capsule, hard - excipient ingredients: gelatin; sodium laureth sulfate; indigo carmine; iron oxide yellow; iron oxide red; microcrystalline cellulose; titanium dioxide; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oxycodone medis is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - oxycodone hydrochloride, quantity: 5 mg - capsule, hard - excipient ingredients: sodium laureth sulfate; iron oxide red; gelatin; microcrystalline cellulose; titanium dioxide; iron oxide yellow; indigo carmine; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oxycodone medis is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - capsule, hard - excipient ingredients: gelatin; iron oxide red; magnesium stearate; titanium dioxide; indigo carmine; microcrystalline cellulose; iron oxide yellow; sodium laureth sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oxycodone medis is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; sodium laureth sulfate; gelatin; titanium dioxide; iron oxide red; indigo carmine; iron oxide yellow; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oxycodone medis is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; calcium silicate; aspartame; colloidal anhydrous silica; microcrystalline cellulose; mannitol; crospovidone; flavour - rizatriptan-medis is indicated for the acute treatment of migraine attacks with or without aura.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - tablet, orally disintegrating - excipient ingredients: aspartame; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; magnesium stearate; mannitol; calcium silicate; flavour - rizatriptan-medis is indicated for the acute treatment of migraine attacks with or without aura.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin; macrogol 3350 - voriconazole-medis is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets.